Stoke Therapeutics Files 8-K with Material Agreement
Ticker: STOK · Form: 8-K · Filed: Feb 18, 2025 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | 8-K |
| Filed Date | Feb 18, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, corporate-event
TL;DR
Stoke Therapeutics just signed a big deal, filing an 8-K on Feb 14th.
AI Summary
On February 14, 2025, Stoke Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Other Events, with financial statements and exhibits provided. The company, formerly known as ASOthera Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in Bedford, Massachusetts.
Why It Matters
This filing indicates a significant new agreement for Stoke Therapeutics, which could impact its strategic direction and financial future.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities that are not yet fully understood.
Key Numbers
- 001-38938 — SEC File Number (Identifies the company's filings with the SEC)
- 47-1144582 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- ASOthera Pharmaceuticals, Inc. (company) — Former Company Name
- February 14, 2025 (date) — Date of earliest event reported
- February 18, 2025 (date) — Filing Date
- 45 Wiggins Ave, Bedford, Massachusetts 01730 (location) — Principal Executive Offices
FAQ
What is the nature of the Material Definitive Agreement entered into by Stoke Therapeutics?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on February 14, 2025.
What other information is included in this 8-K filing?
The filing also includes Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was Stoke Therapeutics, Inc. formerly known as?
Stoke Therapeutics, Inc. was formerly known as ASOthera Pharmaceuticals, Inc., with a name change date of October 28, 2014.
Where is Stoke Therapeutics, Inc. headquartered?
Stoke Therapeutics, Inc. is headquartered at 45 Wiggins Ave, Bedford, Massachusetts 01730.
What is the SIC code for Stoke Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Stoke Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 18, 2025 regarding Stoke Therapeutics, Inc. (STOK).